Genexine, Inc.
- Country
- 🇰🇷South Korea
- Ownership
- Public
- Established
- 1999-06-08
- Employees
- 101
- Market Cap
- -
- Website
- http://www.genexine.com
Efficacy and Safety Study of GX-I7 Plus Adjuvant Temozolomide Combination in Patients With Newly Diagnosed Glioblastoma
- Conditions
- Newly Diagnosed Glioblastoma
- Interventions
- Biological: GX-I7Other: Placebo
- First Posted Date
- 2019-08-22
- Last Posted Date
- 2022-03-17
- Lead Sponsor
- Genexine, Inc.
- Registration Number
- NCT04065087
- Locations
- 🇰🇷
St. Vincent Hospital, Suwon-si, Korea, Republic of
A Phase 2, 12-Week, Double-Blind, Efficacy and Safety of GX-G6 in Patients With Uncontrolled Type 2 Diabetes Mellitus
- First Posted Date
- 2019-05-23
- Last Posted Date
- 2019-05-23
- Lead Sponsor
- Genexine, Inc.
- Target Recruit Count
- 78
- Registration Number
- NCT03962010
Study of GX-I7 in Combination With Pembrolizumab in Refractory or Relapsed (R/R) TNBC Subjects(GX-I7-CA-006/KEYNOTE-899)
- Conditions
- Triple Negative Breast Cancer
- Interventions
- First Posted Date
- 2018-11-26
- Last Posted Date
- 2024-03-05
- Lead Sponsor
- Genexine, Inc.
- Target Recruit Count
- 84
- Registration Number
- NCT03752723
- Locations
- 🇰🇷
Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, Korea, Republic of
🇰🇷Ajou Medical Center, Suwon-si, Gyeonggi-do, Korea, Republic of
🇰🇷National Cancer Center, Goyang-si, Korea, Republic of
GX-I7 With Cyclophosphamide in Patients With Metastatic or Recurrent Solid Tumors
- First Posted Date
- 2018-11-07
- Last Posted Date
- 2020-05-14
- Lead Sponsor
- Genexine, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT03733587
- Locations
- 🇰🇷
Seoul National University Bundang Hospital, Seongnam-si, Korea, Republic of
🇰🇷Seoul National University Hospital, Seoul, Korea, Republic of
Safety and Tolerability of GX-G6 in Healthy Male Subjects
- First Posted Date
- 2018-08-29
- Last Posted Date
- 2018-08-29
- Lead Sponsor
- Genexine, Inc.
- Target Recruit Count
- 48
- Registration Number
- NCT03651466
- Locations
- 🇩🇪
NUVISAN, Neu-Ulm, Germany
Dose-escalation Study to Evaluate the Safety and Tolerability of GX-I7 in Patients With Glioblastoma
- First Posted Date
- 2018-08-07
- Last Posted Date
- 2020-11-10
- Lead Sponsor
- Genexine, Inc.
- Target Recruit Count
- 15
- Registration Number
- NCT03619239
- Locations
- 🇰🇷
The Catholic University of Korea Seoul St. Mary's Hospital, Seoul, Seocho, Korea, Republic of
Study to Evaluate Safety and Tolerability of GX-I7 in Patients With Locally Advanced or Metastatic Solid Tumors
- First Posted Date
- 2018-03-27
- Last Posted Date
- 2020-05-11
- Lead Sponsor
- Genexine, Inc.
- Target Recruit Count
- 35
- Registration Number
- NCT03478995
- Locations
- 🇰🇷
Severance Hospital, Seoul, Korea, Republic of
🇰🇷Asan Medical Center, Seoul, Korea, Republic of
🇰🇷Seoul St. Mary's Hospital, of the Catholic University, Seoul, Korea, Republic of
The Combination of GX-188E Vaccination and Pembrolizumab in Patients With HPV 16 and/or 18+ Advanced Cervical Cancer
- First Posted Date
- 2018-02-23
- Last Posted Date
- 2024-03-01
- Lead Sponsor
- Genexine, Inc.
- Target Recruit Count
- 65
- Registration Number
- NCT03444376
- Locations
- 🇰🇷
Inje University Busan Paik Hospital, Busan, Korea, Republic of
🇰🇷Keimyung University Dongsan Medical Center, Daegu, Korea, Republic of
🇰🇷National Cancer Center, Gyeonggi-do, Korea, Republic of
Dose Finding Study of GX-H9 in Paeditaric Patients With Growth Hormone Deficiency
- First Posted Date
- 2017-10-16
- Last Posted Date
- 2020-04-20
- Lead Sponsor
- Genexine, Inc.
- Target Recruit Count
- 56
- Registration Number
- NCT03309891
- Locations
- 🇺🇦
Odessa National Medical University, Odessa Regional Children's Hospital, Odessa, Ukraine
Tolerability, Safety and Pharmacokinetics Study of GX-30 in Total Thyroidectomy or Near Total Thyroidectomy Patients
- Conditions
- Total ThyroidectomyNear-total Thyroidectomy
- Interventions
- Drug: Period 1 GX-30, Period 2 THYROGEN®Drug: Period 1 THYROGEN®, Period 2 GX-30
- First Posted Date
- 2017-09-08
- Last Posted Date
- 2020-09-09
- Lead Sponsor
- Genexine, Inc.
- Target Recruit Count
- 8
- Registration Number
- NCT03276988
- Locations
- 🇰🇷
Pusan National University Hospital, Busan, Korea, Republic of
🇰🇷Korea University Anam Hospital, Seoul, Korea, Republic of
🇰🇷Seoul Asan Medical Center, Seoul, Korea, Republic of